Daily close, T-120 (7/7/25) through T+5. Run-up high $12.64 on 12/18/25, low $7.82 on 8/4/25 (T-120 to T-1). FDA decision 12/22/25. Historical price action, not a forecast.
Positioning before the decision
On Dec 8, 2025, 14 days before the decision date, at-the-money options priced a move of ±25.6% through Jan 16, 2026 (the first listed expiry after the decision; ATM implied volatility 194%). The stock closed +2.0% at the first close across the decision and +2.7% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Yes. The FDA approved the application for Oziltus (denosumab-mobz) on December 22, 2025. The primary source is linked on this page.
What was Oziltus (denosumab-mobz) under FDA review for?
The application covered Osteoporosis-related conditions. The FDA approved the application on December 22, 2025.
How did AMRX stock react to the FDA decision?
On the decision day AMRX moved +2.0%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.